Invo Fertility, Inc. · NASDAQ:IVF
Invo Fertility — Investor Presentation (September 2025)
26 slides from Invo Fertility's investor presentation, September 2025
Slide 1: Life Begins Within – September 2025 Corporate Presentation
LIFE BEGINS WIT HIN S E P T E M B E R 2 0 2 5 C O R P O R AT E P R E S E N TA T I O N NASDAQ: IVF
Slide 2: Forward-Looking Statements
N A SD AQ : I VF F O R WA R D - LO O K I N G S TAT E M E N T S This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements made in this presentati
Slide 3: Our Mission
O UR MI SSI ON We are a specialty healthcare company focused on making advanced fertility care effective, accessible, and empowering for all, through a patient- centered approach that is powered by innovation, compassion and an exceptional team. 3
Slide 4: Key Highlights: Results, Operating Focus & Market Trends
N A SD AQ : I VF KEY H IG HLI GH TS R E S U LT S , O P E R AT I N G F O C U S & MARKET TRENDS R EVE N UE GR O WTH Revenue Growth $7 • Driven by fertility services, including M&A strategy $6.5 $6 Momentum Building Toward Breakeven • Improved cost structure and profitable clinics brought overall $5 Q2
Slide 5: Expanding Our Focus in the Fertility Market
N A SD AQ : I VF C O M PA N Y E V O L U T I O N E X PA N D I N G O U R F O C U S I N T H E F E R T I L I T Y M A R K E T Be y on d ou r de vi ce he r i ta ge t o a co mp re h e ns i ve he a lt hc ar e pr ov ide r + Need different image – to say Fertility center – rather than invocenter Proprietary a
Slide 6: Fertility Outlook: Favorable Macro Trends Providing Tailwinds
N A SD AQ : I VF F E R T IL ITY O UT LO O K FAV O R A B LE M A C R O TREN DS PROVIDING TA I LWI N D S Potential to expand access • ~15% of reproductive-age women are estimated to be experiencing infertility worldwide1 to IVF and tap into underserved market • 96 to 186 million represents the estimate
Slide 7: Fertility Centers
N A SD AQ : I VF ` FERTILITY CENTERS
Slide 8: Fertility Centers
N A SD AQ : I VF FERT IL ITY CEN T ERS 8 0 0 + C Y C L E S I N 2 0 2 4 AC R O S S 3 F E R T I L I T Y C E N T E R S LOCATION Middleton, WI Atlanta, GA Birmingham, AL PROCEDURES IVF, IVC planned IVC, IVF planned IVF and IVC ANNUAL CYCLES ~500 ~150 ~150 Profitable and largest contributor of PROFITABIL
Slide 9: Clinic Revenue Growth
N A SD AQ : I VF R E V E N U E G R O WT H CL INI C REVENUE* $8.0 $7.7 $7.0 $6.0 $5.0 $4.3 $ Millions $4.1 $4.0 $3.0 $2.0 $1.7 $1.0 $0.0 2022 2023 2024 YTD 2025 *Revenue includes both consolidated revenue from Wisconsin Fertility and Atlanta INVO Center, as well as revenue from Birmingham, which is a
Slide 10: Growth Strategy: Become a Leading Provider of Fertility Services and Technology
N A SD AQ : I VF G R O W T H ST R A T E GY BE COME A LEA DING PROVIDE R OF F E R T I LI T Y S E R VI C E S A N D T E C H N O LO GY ACQUIRE FERTILITY CLINICS ANCILLARY BUSINESSES BUILD NEW CLINICS • Acquire fertility market technologies • Offer IVF+IVC (300+/yr cycles) • Profitable, U.S. IVF clinics
Slide 11: Case Study – M&A Strategy: Wisconsin Fertility Institute
N A SD AQ : I VF CA S E ST U D Y – M & A S T RAT E GY W I S C O N S I N F E RT I L I T Y I N ST I T U T E Acquisition Details • One of Wisconsin’s leading fertility centers (rated top-100 in US by Newsweek) • 5,000+ babies born since 2007, averaging 500+ IVF cycles/year over the last 5 years • Stron
Slide 12: Case Study – New-Build Clinic: Bloom Fertility
N A SD AQ : I VF CA S E ST U DY – N E W- B U IL D CL I N IC B LO O M F E R T I LI T Y Clinic Details • INVO Center focused primarily on IVC procedure • Approximately 500 IVC cycles since 2022, averaging around 150 cycles/year • Seasoned team in place Growth Details • Add IVF and hire new doctor to e
Slide 13: Why Join INVO Fertility?
N A SD AQ : I VF A D V A N TA G E S W H Y J O I N I N VO F E R T I L I T Y ? Like-Minded Partners; Synergies • Focus on medical practice and patient services, while INVO corporate provides centralized administration, finance, marketing, human resources and other services • Strength in unity – genera
Slide 14: Technology
NAS DA Q: IV F TECHNOLOGY
Slide 15: Leveraging Technology to Expand Access
N A SD AQ : I VF L E V E R A G I N G T E C H N O LO GY T O E X PA N D AC C E S S Medical device heritage Unique INVOcell-enabled IVC procedure improves lab efficiency and capacity, increases fertility service supply and helps to reduce the risk of mix-up occurrences, while providing a more connected
Slide 16: INVOcell: Unique Product, Revolutionary Procedure
N A SD AQ : I VF INVOce ll® U N I Q U E P R O D U C T, R E VO L U T I O N A R Y P R O C E D U R E For clinical pregnancy rates, INVOcell outcomes are comparable to IVF and more effective than IUI. ADVANCED TREATMENT IUI INVOcell (IVC) IVF 8-10%* ~57.1%** ~51.8%** SUCCESS SUCCESS SUCCESS *Fauque P, L
Slide 17: Financials
NAS DA Q: IV F FINANCIALS
Slide 18: Income Statement Highlights
N A SD AQ : I VF I N CO M E STAT E M E N T H I G H L I G H T S (USD) FY 2022 FY 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 FY 2024 Q1 2025 Q2 2025 Clinic 614,854 2,862,574 1,537,199 1,807,921 1,418,011 1,687,300 6,450,431 1,621,553 1,832,094 Product 207,342 158,001 39,087 28,676 15,140 -1,334 81,569 15,63
Slide 19: Balance Sheet Highlights
N A SD AQ : I VF BA LANC E SHEET HIGHLIGHTS (USD) 12/31/2023 12/31/2024 6/30/2025 Cash and cash equivalents 232,424 619,520 549,181 Other current assets 1,027,351 698,811 850,172 Lease right of use 5,740,929 2,283,784 2,160,380 Intangible assets 4,093,431 3,275,931 1,535,845 Goodwill 5,878,986 5,878
Slide 20: Stock Data: Key Information
N A SD AQ : I VF S TO C K D ATA K E Y I N F O R M AT I O N INVO Fertility (Nasdaq: IVF) Data as of 8/29/2025* Market capitalization $4.1 million Stock price | 52-week range $0.95 | $0.95 - $51.12 Common shares issued and outstanding (as of August 14, 2025) 4,363,016 Average volume 199,265 * Unless s
Slide 21: Summary
Ovo fertility NASDAQ: IVF SUMMARY
Slide 22: Why Invest in INVO Fertility? Key Takeaways
NAS DA Q: IV F W HY INVE ST IN INVO FERTILITY? K E Y TA K E AW AY S Growing Clinic M&A Focus to Drive Integration of Unique Industry Momentum Building Operations Added Growth Technologies Tailwinds Towards Breakeven • Opened INVO • Prioritizing M&A over • Building upon • Large supply and • Adjusted
Slide 23: People
NAS DA Q: IV F PEOPLE
Slide 24: Leadership Team
N A SD AQ : I VF LEADERSHIP TEAM E X P E R I E N C E D & D E D I C AT E D Doctors Andrea Goren Gretchen Collins Sue Ellen Carpenter Nick Cataldo Steve Shum CEO CFO Lab Directors April McGhee Bo Mitrovic Wael Megid Chad Johnson Lisa Ray Clinical Operations Business Development September 2025 © 2025 I
Slide 25: Board of Directors
N A SD AQ : I VF BOAR D O F D IRECTOR S I N DE P E N D E N T & E N G A G E D Steve Shum Trent Davis Rebecca Messina Barbara Ryan Matthew Szot CEO, Director Independent Director Independent Director Independent Director Independent Director September 2025 © 2025 INVO Fertility, Inc. 25
Slide 26: Thank You
THANK YOU For more information, please contact: Steve Shum, CEO Andrea Goren, CFO 978-878-9505 x506 978-878-9505 x520 sshum@invobio.com agoren@invobio.com
INVO Fertility — Investor Presentation (September 2025) on 6ix